ArticleInternational journal of microbiology2012
Development of Class IIa Bacteriocins as Therapeutic Agents.
Article in International journal of microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 87 citations in OpenAlex.
- Engineered antimicrobial-derived peptides to manipulate mixed microbial systems.Microbiology spectrum · 2026Article
- Expression of Enterocin A in Saccharomyces cerevisiae.Probiotics and antimicrobial proteins · 2026Article
- Heterologous Expression of Plantaricin 423 and Mundticin ST4SA in Saccharomyces cerevisiae.Probiotics and antimicrobial proteins · 2024Article
- Bacteriocins: potentials and prospects in health and agrifood systems.Archives of microbiology · 2024Review
- The high-throughput solid-phase extraction ofFrontiers in molecular biosciences · 2024Article
- Immunomodulation, Bioavailability and Safety of Bacteriocins.Life (Basel, Switzerland) · 2023Review
- Use of Bacteriocins and Bacteriocinogenic Beneficial Organisms in Food Products: Benefits, Challenges, Concerns.Foods (Basel, Switzerland) · 2022Review
- Mining Biosynthetic Gene Clusters inMicroorganisms · 2022Article
- Antimicrobial Mechanisms of Enterocin CHQS Against Candida albicans.Current microbiology · 2022Article
- Review
- Manganese Privation-Induced Transcriptional Upregulation of the Class IIa Bacteriocin Plantaricin 423 in Lactobacillus plantarum Strain 423.Applied and environmental microbiology · 2021Article
- Review
- Antiviral activities and applications of ribosomally synthesized and post-translationally modified peptides (RiPPs).Cellular and molecular life sciences : CMLS · 2021Review
- Synergistically-acting Enterocin LD3 and Plantaricin LD4 Against Gram-Positive and Gram-Negative Pathogenic Bacteria.Probiotics and antimicrobial proteins · 2021Article
- Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations.FEMS microbiology reviews · 2021Review
- Review
- Bacteriocin-a potential antimicrobial peptide towards disrupting and preventing biofilm formation in the clinical and environmental locales.Environmental science and pollution research international · 2020Review
- Application of bacteriocins in food preservation and infectious disease treatment for humans and livestock: a review.RSC advances · 2020Review
- Heterologous Expression of the Class IIa Bacteriocins, Plantaricin 423 and Mundticin ST4SA, inFrontiers in microbiology · 2020Article
- The membrane topology of immunity proteins for the two-peptide bacteriocins carnobacteriocin XY, lactococcin G, and lactococcin MN shows structural diversity.MicrobiologyOpen · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and chemical modifications to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their production and purification. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Recent results suggest that class IIa bacteriocins show promise as a class of therapeutic agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.